The past few years have seen a rapid increase in the development and use of new drugs to treat obesity, many of which target the incretin system. A new study has reported the phase I results of AMG 133 (also known as maridebart cafraglutide), which is a bispecific molecule consisting of a glucose-dependent insulinotropic peptide receptor (GIPR) antagonist antibody conjugated to two glucagon-like peptide 1 (GLP1) agonists.

The researchers confirmed the activity of AMG 133 in cell models and preclinical animal models. In cell-based functional assays, AMG 133 had GIPR antagonist and GLP1 receptor agonist activity. Treating male obese mice and cynomolgus monkeys with AMG 133 resulted in reduced body weight and improved metabolic parameters, including blood levels of glucose.